GI Cancer

Patients expect substantial benefits to justify longer duration of adjuvant chemotherapy

Cancer patient preferences are for a shorter duration of adjuvant chemotherapy, with Australian research showing many are not prepared to undergo longer duration of chemotherapy unless the treatment confers a big survival benefit. The finding comes from a study of Australian patients enrolled in the SCOT trial, a randomised phase 3 trial of three months ...

Already a member?

Login to keep reading.

© 2022 the limbic